Who are Metformin plus pioglitazone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-plus-pioglitazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Metformin plus pioglitazone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin plus pioglitazone (Metformin plus pioglitazone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide plus thiazolidinedione. Area: Diabetes.

phase 3 Biguanide plus thiazolidinedione PPAR-γ (pioglitazone component); metformin target not fully elucidated but involves mitochondrial function Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin plus pioglitazone (Metformin plus pioglitazone) — Nanjing First Hospital, Nanjing Medical University. Metformin reduces hepatic glucose production and improves insulin sensitivity, while pioglitazone enhances insulin sensitivity by activating peroxisome proliferator-activated receptor gamma (PPAR-γ) in adipose and muscle tissue.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Metformin plus pioglitazone TARGET	Metformin plus pioglitazone	Nanjing First Hospital, Nanjing Medical University	phase 3	Biguanide plus thiazolidinedione	PPAR-γ (pioglitazone component); metformin target not fully elucidated but involves mitochondrial function

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide plus thiazolidinedione class)

Nanjing First Hospital, Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin plus pioglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-plus-pioglitazone. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab